Related Experiment Videos
Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors
Daniel J Scherer1, Adam J Nelson1, Peter J Psaltis1
1South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
Insights
New PCSK9 inhibitors offer a novel approach to significantly reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular events, especially for patients unresponsive or intolerant to statins.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Statins effectively lower low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events.
- Many patients require additional therapies due to persistent high LDL-C or statin intolerance.
- Novel therapeutic strategies are needed for comprehensive cardiovascular risk reduction.
Purpose of the Study:
- To review the current experience with PCSK9 inhibitors.
- To discuss the implications of PCSK9 inhibitors for clinical practice.
- To evaluate the cost-effectiveness of PCSK9 inhibitors.
Main Methods:
- Review of clinical trial data on PCSK9 inhibitors.
- Analysis of patient outcomes with PCSK9 inhibitor therapy.
- Assessment of economic evaluations for PCSK9 inhibitors.
Main Results:
- PCSK9 inhibitors demonstrate significant LDL-C reduction.
- These agents offer a new therapeutic option for high-risk patients.
- Clinical use and cost-effectiveness data are being established.
Conclusions:
- PCSK9 inhibitors represent a significant advancement in managing hyperlipidemia.
- Further research and real-world data will refine their clinical application.
- PCSK9 inhibitors hold promise for improving cardiovascular outcomes.
Abstract:
Over the past quarter century, clinical trials have consistently demonstrated that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of major adverse cardiovascular events. However, the findings that many patients continue to experience events or harbour inappropriately high LDL-C levels despite intensive statin therapy and the clinical reality of statin intolerance suggests that additional therapeutic strategies are required in order to achieve more effective reductions in cardiovascular risk. The emergence of inhibitory monoclonal antibodies targeted against proprotein convertase subtilisin kexin type 9 (PCSK9) provides a novel approach to reducing LDL-C levels. The current experience of PCSK9 inhibitors and implications for clinical use and cost effectiveness will be reviewed.